Dr Adie Viljoen and Dr Mohamed Elnaggar address the challenge of “Treatment Limbo”, in dyslipidaemia management, where patients fail to achieve low-density lipoprotein cholesterol (LDL-C) targets yet remain ineligible for advanced therapies. They introduce a guideline-aligned, alternative approach that tailors treatment to baseline LDL-C and distance to goal, supporting timely intervention and helping to reduce the risk of recurrent cardiovascular events.